TY - JOUR
T1 - Nuclear Medicine Imaging in Neuroblastoma
T2 - Current Status and New Developments
AU - Samim, Atia
AU - Tytgat, Godelieve A M
AU - Bleeker, Gitta
AU - Wenker, Sylvia T M
AU - Chatalic, Kristell L S
AU - Poot, Alex J
AU - Tolboom, Nelleke
AU - van Noesel, Max M
AU - Lam, Marnix G E H
AU - de Keizer, Bart
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/4/4
Y1 - 2021/4/4
N2 - Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine has been essential for the staging and response assessment of neuroblastoma. Currently, the standard nuclear imaging technique is meta-[123I]iodobenzylguanidine ([123I]mIBG) whole-body scintigraphy, usually combined with single-photon emission computed tomography with computed tomography (SPECT-CT). Nevertheless, 10% of neuroblastomas are mIBG non-avid and [123I]mIBG imaging has relatively low spatial resolution, resulting in limited sensitivity for smaller lesions. More accurate methods to assess full disease extent are needed in order to optimize treatment strategies. Advances in nuclear medicine have led to the introduction of radiotracers compatible for positron emission tomography (PET) imaging in neuroblastoma, such as [124I]mIBG, [18F]mFBG, [18F]FDG, [68Ga]Ga-DOTA peptides, [18F]F-DOPA, and [11C]mHED. PET has multiple advantages over SPECT, including a superior resolution and whole-body tomographic range. This article reviews the use, characteristics, diagnostic accuracy, advantages, and limitations of current and new tracers for nuclear medicine imaging in neuroblastoma.
AB - Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine has been essential for the staging and response assessment of neuroblastoma. Currently, the standard nuclear imaging technique is meta-[123I]iodobenzylguanidine ([123I]mIBG) whole-body scintigraphy, usually combined with single-photon emission computed tomography with computed tomography (SPECT-CT). Nevertheless, 10% of neuroblastomas are mIBG non-avid and [123I]mIBG imaging has relatively low spatial resolution, resulting in limited sensitivity for smaller lesions. More accurate methods to assess full disease extent are needed in order to optimize treatment strategies. Advances in nuclear medicine have led to the introduction of radiotracers compatible for positron emission tomography (PET) imaging in neuroblastoma, such as [124I]mIBG, [18F]mFBG, [18F]FDG, [68Ga]Ga-DOTA peptides, [18F]F-DOPA, and [11C]mHED. PET has multiple advantages over SPECT, including a superior resolution and whole-body tomographic range. This article reviews the use, characteristics, diagnostic accuracy, advantages, and limitations of current and new tracers for nuclear medicine imaging in neuroblastoma.
KW - Neuroblastoma
KW - Nuclear medicine
KW - Radionuclide imaging
KW - [C]mHED
KW - [F]F-DOPA
KW - [F]FDG
KW - [F]mFBG
KW - [Ga]Ga-DOTA peptides
KW - [I]mIBG
UR - http://www.scopus.com/inward/record.url?scp=85104666951&partnerID=8YFLogxK
U2 - 10.3390/jpm11040270
DO - 10.3390/jpm11040270
M3 - Review article
C2 - 33916640
SN - 2075-4426
VL - 11
JO - Journal of personalized medicine
JF - Journal of personalized medicine
IS - 4
M1 - 270
ER -